search
Back to results

The Minimum Effective Concentration of Lidocaine for Ultrasound-guided Axillary Block for Arterio-venous Fistula Creation Surgery

Primary Purpose

Anesthesia

Status
Unknown status
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Lidocaine 2% Injectable Solution
Sponsored by
Far Eastern Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anesthesia

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ASA classification I to III
  • Operation site : First time undergone surgery

Exclusion Criteria:

  • ASA classification IV to V
  • Previous operation at surgical site before
  • Allergy to local anesthetics
  • Infectious state of injection point
  • Neuromuscular disease causing preoperative numbness or weakness of extremities
  • History of vascular thromboembolism including stroke, pulmonary embolism
  • Peripheral neuropathy
  • Patient with psychiatric disease
  • Coagulopathy, or patient taking anti-coagulant

Sites / Locations

  • Chen Yen HuaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Participant

Arm Description

Outcomes

Primary Outcome Measures

Minimal effective concentration of lidocaine solution
To test the sensory and motor blockade after local anesthetics being injected by dermatome testing of upper extremity

Secondary Outcome Measures

Functional Dialysis
Percentage (%) of patient who under gone hemodialysis via the fistula created

Full Information

First Posted
September 8, 2021
Last Updated
September 21, 2021
Sponsor
Far Eastern Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05063578
Brief Title
The Minimum Effective Concentration of Lidocaine for Ultrasound-guided Axillary Block for Arterio-venous Fistula Creation Surgery
Official Title
The Minimum Effective Concentration of Lidocaine for Ultrasound-guided Axillary Block for Arterio-venous Fistula Creation Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 20, 2021 (Anticipated)
Primary Completion Date
August 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Far Eastern Memorial Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The arteriovenous fistula creation (AVF creation) surgery is essential among patients with end stage renal disease who require hemodialysis. The fistula usually locates at forearm, and is created by connecting artery and vein through surgery. Patients undergone hemodialysis through the fistula six weeks later if fistula becoming mature, which means patent vessel diameter and enough flow for hemodialysis. The primary failure rate of arteriovenous fistula creation is about 20% to 40% according to previous research data. Thrombosis is the most common cause of fistula failure, which require surgical intervention after arteriovenous fistula surgery. Anesthetic technique influences surgical outcome of arteriovenous fistula. General anesthesia, regional anesthesia, and local anesthesia are both wide-used methods. Regional anesthesia with nerve block remains the most popular method for arteriovenous fistula creation. The vessel dilation effect of regional anesthesia helps not only dilatation of artery and vein, but also the fistula itself, and promotes the successful functional dialysis. Various type of nerve block are used as anesthetic method for AVF creation surgery. People requiring hemodialysis usually have multiple underlying disease involving other major organ such as heart, lung, liver, and the endocrine system. They are more vulnerable to systemic intravenous anesthetic medication. The metabolic rate and pharmacodynamics of local anesthetic may also alter due to multiple systemic disease when compared with healthy adults. The optimal concentration of lidocaine for AVF creation when using axillary block has not yet been studied. This research is conducted for dosing response of different concentration of lidocaine when using axillary block for AVF creation surgery. We aim to investigate the optimal low effective concentration, the MEC90, which defined as 90% of patients can tolerate the operation at this concentration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Participant
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Lidocaine 2% Injectable Solution
Intervention Description
Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
Primary Outcome Measure Information:
Title
Minimal effective concentration of lidocaine solution
Description
To test the sensory and motor blockade after local anesthetics being injected by dermatome testing of upper extremity
Time Frame
Before the operation
Secondary Outcome Measure Information:
Title
Functional Dialysis
Description
Percentage (%) of patient who under gone hemodialysis via the fistula created
Time Frame
six weeks after the operation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ASA classification I to III Operation site : First time undergone surgery Exclusion Criteria: ASA classification IV to V Previous operation at surgical site before Allergy to local anesthetics Infectious state of injection point Neuromuscular disease causing preoperative numbness or weakness of extremities History of vascular thromboembolism including stroke, pulmonary embolism Peripheral neuropathy Patient with psychiatric disease Coagulopathy, or patient taking anti-coagulant
Facility Information:
Facility Name
Chen Yen Hua
City
New Taipei City
ZIP/Postal Code
220
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yen Hua Chen, MD
Phone
886910003805
Email
yanhua0624@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Minimum Effective Concentration of Lidocaine for Ultrasound-guided Axillary Block for Arterio-venous Fistula Creation Surgery

We'll reach out to this number within 24 hrs